基于外泌体的多重抗肿瘤治疗与同步影像监测
研究制备载阿霉素和5-氨基乙酰丙酸(ALA)的HCT116结直肠癌外泌体纳米探针(TEX@DOX@ALA),利用预靶向技术经68Ga-L-NETA-DBCO点击化学实现PET/CT可视化外泌体肿瘤聚集,并在荷瘤小鼠中评估化疗联合光动力治疗的疗效与安全性。
要点
- 载药不影响HCT116外泌体膜结构与功能,荧光成像示24小时肿瘤信号最高。
- PET/CT预靶向点击化学可清晰显示皮下及原位结肠肿瘤的外泌体聚集。
- TEX@DOX@ALA联合光动力与化疗组抑瘤效果最佳,生存时间最长(36天,37.5%)。
核心结论
- 成功构建整合PET成像组件与治疗药物的外泌体纳米探针。
- 该载药外泌体系统可能有效靶向肿瘤,并实现化疗与光动力的协同抗肿瘤作用。
研究设计与样本
- 制备人结直肠癌HCT116细胞来源外泌体,负载阿霉素与光动力治疗剂5-氨基乙酰丙酸(ALA),命名为TEX@DOX@ALA。
- 先用Cy5荧光染料标记物(TEX@DOX@ALA@Cy5)行荧光成像检查肿瘤摄取。
- 荷瘤小鼠先注射叠氮(N3)标记的TEX@DOX@ALA@N3,24小时后注射68Ga-L-NETA-DBCO,经体内点击化学行PET/CT成像。
- 七组荷瘤小鼠接受不同治疗,记录肿瘤大小、动物体重和生存时间。
- 采集血液及心、肺、肝、肾、脾组织行血液学分析和H&E染色。
主要发现
- 载药过程未影响HCT116外泌体膜的结构或功能。
- 荧光成像实验中,注射TEX@DOX@ALA@Cy5后肿瘤可见较高荧光,24小时信号最高。
- 皮下及原位结肠肿瘤荷瘤小鼠的PET/CT图像中肿瘤可见清晰放射性,提示外泌体在肿瘤中聚集成功。
- TEX@DOX@ALA联合光动力治疗与化疗组较其他组抑瘤效果最佳,生存时间最长(36天,37.5%)。
- 组织学观察和血液生化分析未发现明显损伤,提示多药负载外泌体的安全性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor-derived exosomes (TEX) have shown great potential for drug delivery and tumor targeting. Here, we developed a novel multi-drug loaded exosomes nanoprobe for combined antitumor chemotherapy and photodynamic therapy, and monitoring the drug delivery capabilities with pre-targeting technique. METHODS: TEX of human colorectal cancer HCT116 was prepared, and Doxorubicin and the photodynamic therapy agent 5-aminolevulinic acid (ALA) were loaded and named as TEX@DOX@ALA. Tumor uptake was first examined using fluorescence imaging of the fluorescent dye Cy5 (TEX@DOX@ALA@Cy5). Visualization of exosome aggregation in tumor were realized by positron-emission tomography/computed tomography (PET/CT) with pre-targeting technique. Tumor-bearing mice were first injected with TEX@DOX@ALA labeled with azide (N3) (TEX@DOX@ALA@N3), and then 68Ga-(2,2'-((6-amino-1-(4,7-bis (carboxymethyl)-1,4,7-triazonan-1-yl) hexan-2-yl) azanediyl) diacetic acid-dibenzocyclooctyne (68Ga-L-NETA-DBCO) was injected after 24 h for PET/CT imaging via in vivo click chemistry. For the antitumor therapy with photodynamic and/or chemotherapy, seven groups of tumor-bearing mice with different therapy were monitored, and the tumor size, animal weight and the survival time were recorded. Furthermore, the samples of blood and interested tissues (heart, lung, liver, kidney, and spleen) were harvested for hematological analysis and H&E staining. RESULTS: The drug loading process did not influence the structure or the function of the HCT116 TEX membranes. In a fluorescence imaging experiment, higher fluorescence could be seen in tumor after TEX@DOX@ALA@Cy5 injected, and reached the highest signal at 24 h. From PET/CT images with subcutaneous and orthotopic colon tumor-bearing mice, clear radioactivity could be seen in tumors, which suggested the successes of TEX accumulation in tumors. TEX@DOX@ALA group with photodynamic therapy and chemotherapy had the best tumor inhibition effect compared with the other groups, with the longest survival time (36 days, 37.5%). No significant damage was found on histological observation and the blood biochemical analysis, which suggested the safety of the multi-drug loaded exosomes. CONCLUSIONS: We successfully engineered an exosome-based nanoprobe integrating PET imaging components and therapeutic drugs. This drug-loaded exosome system may effectively target tumors and enable synergistic chemotherapeutic and photodynamic antitumor effects.
引用
- Qian R, Jing B, Jiang D, et al. Multi-antitumor therapy and synchronous imaging monitoring based on exosome. Eur J Nucl Med Mol Imaging. 2022. PMID: 35091755. doi:10.1007/s00259-022-05696-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。